Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:09 2024-07-12 am EDT			5-day change	1st Jan Change
5.44 ^EUR	-3.72%		-23.27%	-52.86%

Jul. 11	ADOCIA : price target reduced by Oddo BHF	CF
Jul. 10	Adocia, Tonghua Dongbao End Insulin Combo License Deal	MT

Adocia appoints Director of Operations

June 04, 2024 at 07:15 am EDT

Adocia announces the appointment of Mathieu-William Gilbert to the position of Director of Operations, having previously been Vice-President of Strategic Projects within International Commercial Operations at Novo Nordisk.

Previously, Mathieu-William Gilbert held the position of Vice President and General Manager of six Latin American subsidiaries at the Danish healthcare group, with responsibility for all activities in the region.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	NOVO NORDISK A/S	980.3 DKK	+1.34%	+0.65%	636B
	ADOCIA	5.44 EUR	-3.72%	-23.27%	89.23M

Latest news about Adocia

ADOCIA : price target reduced by Oddo BHF	Jul. 11	CF
Adocia, Tonghua Dongbao End Insulin Combo License Deal	Jul. 10	MT
Adocia: end of insulin partnership program	Jul. 10	CF
Adocia appoints Director of Operations	Jun. 04	CF
Adocia Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer	Jun. 03	CI
Adocia SA announced that it has received funding	May. 30	CI
Adocia SA announced that it has received ?2 million in funding	May. 13	CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Adocia: announces fund-raising	Mar. 22	CF
Adocia SA announced that it expects to receive ?2 million in funding	Mar. 20	CI
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes	Nov. 09	CI
Adocia: positive study data for BC Combo	23-10-23	CF
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-18	CI
Adocia: refinancing operations completed	23-07-26	CF
Adocia SA announced that it has received ?9.999993 million in funding from Bpifrance Investissement SAS, Vester Finance SA	23-07-19	CI
Adocia: exclusive right to negotiate M1Pram with Sanofi	23-07-06	CF
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug	23-07-06	MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram	23-07-05	CI
Adocia SA announced that it expects to receive â‚¬10 million in funding	23-07-04	CI
Adocia Requests Trading Halt on Euronext Paris	23-06-01	MT
Adocia: listing suspended pending a press release	23-06-01	CF
Adocia SA Auditor Raises 'Going Concern' Doubt	23-04-27	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	23-03-16
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI

Chart Adocia

Duration

Period

More charts

Company Profile

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q2 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for Adocia

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.44 EUR

Average target price

6.3 EUR

Spread / Average Target

+15.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADOCIA	-52.86%	89.23M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs